Cronos Group Inc. (CRON)
NASDAQ: CRONHealth Care Medicinal Chemicals and Botanical Products USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRON stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.11B
- P/E (TTM)
- 19.00
- EPS (TTM)
- $0.16
- Dividend yield
- None
- 52-week range
- 2.35 – 3.91
- Day range
- 3.02 – 3.12
- Volume / Avg
- 1.92M / 1.07M
- Beta
- —
- Shares outstanding
- 366.47M
52-week range
CRON stock today
On Nov 20, CRON ended the session at $3.04, shedding $0.04 (1.30%), versus the S&P 500's 3.70% decline. At this level, CRON sits in the middle of its 52-week range of $2.35 to $3.91: 22.3% below the high, set on Nov 5, 2026 and 29.4% above the low. CRON is up 15.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 28.3%.
Cronos Group trades at 19.0x its trailing twelve-month earnings per share of $0.16.
Summary generated from market data by MetaCap's automated system. Methodology
About Cronos Group
Company profileCronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. Michael Ryan Gorenstein J.D.
- Headquarters
- Stayner, ON
- Employees
- 610
- Website
- thecronosgroup.com
Financial highlights
Full financialsIn fiscal 2025, Cronos Group generated $146.6 million in revenue, up 24.6% from fiscal 2024, its 8th consecutive year of revenue growth. Cronos Group reported a net loss of $9.4 million, compared with net income of $41.1 million a year earlier. Gross margin was 42.8% (up from 21.4%) and operating margin -11.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $146.59M | $117.61M | $87.24M | $86.75M | $64.56M |
| Growth | +24.63% | +34.82% | +0.57% | +34.37% | +38.19% |
| Net income | $-9.45M | $41.08M | $-73.96M | $-168.73M | $-396.11M |
| EPS (diluted) | $-0.02 | $0.11 | $-0.19 | $-0.45 | $-1.07 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$2.93-3.62%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.04 vs $0.03
- Surprise
- +33.33%
CRON news
All CRON news- Duke Robotics Announces Expansion of IC Drone Platform into Greece Through Strategic Collaboration with CRONOSGlobeNewswireDUKR, CRON
- Which of These 5 Cannabis Stocks Has the Strongest Balance Sheet?NasdaqCRON, ACB, CGC, SNDL
- Cronos Group Inc. Reports Q3 2026 Net Revenue of $63.5 million and Completes CanAdelaar AcquisitionNasdaq
- Cronos rises as 75% topline growth powers Q3 beatSeeking Alpha
- Cronos Group Reports 2026 Third Quarter ResultsGlobeNewswire
- Baker Hughes Wins Major Subsea Contract From Eni for Cronos GasNasdaqBKR, E, EOG, CVE
- Are Medical Stocks Lagging Cronos Group (CRON) This Year?NasdaqCRON, AMGN
- Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis CompanyGlobeNewswire
Cronos Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. Subordinate Voting Shares | 8.68 | -7.17% | $1.48B | vs CRON |
| OBIOOrchestra BioMed Holdings Inc. | 6.58 | -6.00% | $517.88M | vs CRON |
| SNDLSNDL Inc. | 1.17 | -5.65% | $285.20M | vs CRON |
| TLRYTilray Brands Inc. | 1.89 | -8.70% | $279.32M | vs CRON |
| ACBAurora Cannabis Inc. | 4.16 | -2.35% | $273.50M | vs CRON |
| USNAUSANA Health Sciences Inc. | 12.94 | -1.67% | $239.24M | vs CRON |
| MDWDMediWound Ltd. | 13.59 | +0.37% | $195.56M | vs CRON |
| CGCCanopy Growth Corporation | 0.427 | -9.97% | $191.99M | vs CRON |
Indexes, lists and sector
Cronos Group stock FAQ
What is Cronos Group's stock price today?
CRON last traded at $3.04 as of Nov 20, 4:00 PM EST, down 1.30% on the day. Prices are delayed at least 15 minutes.
What is CRON's P/E ratio?
CRON trades at a trailing P/E ratio of 19.00.
Who is Cronos Group's CEO?
Mr. Michael Ryan Gorenstein J.D. is the chief executive officer of Cronos Group Inc., which has about 610 employees.
What is the CRON 52-week high?
The 52-week high for CRON is $3.91 and the 52-week low is $2.35. The stock is currently 22.3% below its high.